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STATEMENT OF TRANSLATIONAL RELEVANCE  
Parameters of tumor perfusion, such as iAUC and K
trans
, from dynamic contrast-enhanced 
MRI have shown potential as biomarkers in clinical trials to predict tumor response to anti-
angiogenics and other adjuvant therapies. Unfortunately, the biological interpretation of these 
functional parameters with respect to changes in tumor vessel morphology remains unclear, in 
part because many studies compared functional changes that occur on a millimeter resolution in 
MR with structural changes that occur on a micrometer level in histology. By using in vivo 
imaging and 3D analysis in preclinical and human tumors, we demonstrate a clinically feasible 
method that links functional MR parameters to structural features of vessels. We find that 
functional parameters reflect vessel morphology, that this dependence varies with vascularity and 
with region, and that the dependence is affected by anti-angiogenic therapy. By linking 
functional parameters to structural ones, our findings could improve the biological interpretation 
of these biomarkers.   
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ABSTRACT  
 
Purpose: Tumor vessels influence the growth and response of tumors to therapy. Imaging 
vascular changes in vivo using dynamic contrast-enhanced MRI (DCE-MRI) has shown potential 
to guide clinical decision making for treatment. However, quantitative MR imaging biomarkers 
of vascular function have not been widely adopted, partly because their relationship to structural 
changes in vessels remains unclear. We aimed to elucidate the relationships between vessel 
function and morphology in vivo.   
Methods: Untreated preclinical tumors with different levels of vascularization were imaged 
sequentially using DCE-MRI and computed tomography (CT). Relationships between functional 
parameters from MR (iAUC, K
trans
, and BATfrac) and structural parameters from CT (vessel 
volume, radius, and tortuosity) were assessed using linear models. Tumors treated with anti-
VEGFR2 antibody were then imaged to determine whether anti-angiogenic therapy altered these 
relationships. Finally, functional-structural relationships were measured in ten patients with liver 
metastases from colorectal cancer.   
Results: Functional parameters iAUC and K
trans
 primarily reflected vessel volume in untreated 
preclinical tumors. The relationships varied spatially and with tumor vascularity, and were 
altered by anti-angiogenic treatment. In human liver metastases, all three structural parameters 
were linearly correlated with iAUC and K
trans
. For iAUC, structural parameters also modified 
each other’s effect.   
Conclusions: Our findings suggest that MR imaging biomarkers of vascular function are linked 
to structural changes in tumor vessels, and that anti-angiogenic therapy can affect this link. Our 
work also demonstrates the feasibility of 3D functional-structural validation of MR biomarkers 
in vivo to improve their biological interpretation and clinical utility. 
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INTRODUCTION  
Solid tumors develop complex vascular networks during their growth. This vascular 
network not only provides nutrients and oxygen supply to tumor cells, but also plays a critical 
role in response to treatment. Changes in the vascular structure and function can alter blood flow, 
which can affect the delivery of chemotherapeutics to the tumor, as well as result in regions of 
hypoxia that can change the response of the tumor to radiotherapy (1,2). Non-invasive imaging 
of these changes during the course of treatment could aid cancer physicians to guide clinical 
decisions and refine treatment (3,4). 
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a non-invasive, 
functional technique that can image vascular changes in vivo. These changes are quantified from 
the uptake and distribution of a bolus of contrast agent injected intravenously, resulting in 
parameters such as the volume transfer constant (K
trans
), the initial area-under-the-curve of 
contrast uptake up to a predetermined time point (iAUC), and the fraction of voxels enhancing at 
the time of bolus arrival (BATfrac) (3,5). Changes in these imaging biomarkers have been used to 
monitor pharmacodynamic changes in response to anti-angiogenic treatment and to measure 
biological changes that occur in tumor vessels (6–10). They have also been correlated with 
clinical outcome in many studies (11–17). However, these biomarkers have limited influence in 
clinical decision-making because their relationship to changes at the morphological level remains 
unclear (4,18,19), limiting the potential to adapt therapy in light of response. The linking of these 
MR parameters to morphological changes in vessels (i.e., biological validation) would not only 
improve their utility in the clinic, but could also provide mechanistic insights of the biological 
actions exerted by cancer therapies (18–20). 
Biological validation of these MR parameters to vessel morphology has conventionally 
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been performed by correlating relationships between functional parameters (e.g., K
trans
) derived 
from DCE-MRI scans with structural parameters (i.e., microvascular density) derived from 
histology. Although correlations have been found in some cancers (4), the results have been 
conflicting, in part because they compare MRI parameters derived from 3D volumetric images to 
histological parameters derived from 2D slices (4,21). A recent consensus document identified 
incomplete imaging-biology validation as a major shortcoming in translating imaging biomarkers 
and strongly recommended the use of 3D techniques to improve comparisons between vessel 
function and structure (21).  
In this study, we attempt to tackle this shortcoming by measuring the 3D relationship 
between functional imaging parameters and structural vascular features in vivo to facilitate 
clinical utility. To achieve this aim, we used improved imaging (22) and 3D segmentation 
techniques (23) to extract functional parameters derived from DCE-MRI and structural 
parameters derived from contrast-enhanced CT performed in vivo.   Relationships were first 
assessed in untreated tumors from two different preclinical models with high and low levels of 
vascularization. We then tested whether these relationships reproduced in an independent cohort 
of mice and whether they were altered when tumors were treated with an anti-angiogenic agent. 
Finally, we applied the methodology on imaging data from patients with liver metastases from 
colorectal cancer to test its clinical feasibility and to test whether the preclinical relationships 
held true for clinical data.
 7 
MATERIALS AND METHODS 
Cell lines 
 Two cell lines, mouse colon carcinoma MC38 and human pharyngeal carcinoma FaDu, 
were used for imaging experiments. MC38 cells, generated through chemical induction of colon 
carcinoma in C57BL/6 mouse strain, were a gift (Dr. Carlos Arteaga, Vanderbilt University).  
FaDu cells (original source ATCC) were analyzed by STR profile analysis; cells matched the 
ATCC reference at 8/9 markers and Cancer Genome Project STR data at 13/13 markers (CRUK 
Cancer Centre Genomics Facility, Leeds, UK). Cells were checked regularly using MycoAlert 
Mycoplasma Detection Kit (Lonza) to ensure they were negative for mycoplasma. Details 
regarding cell culture conditions are in Supplementary Methods. 
 
Animal models 
 To assess changes in vessel morphology and perfusion during tumor growth (cohort 1), 
we imaged C57BL/6 mice bearing MC38 tumors (n=16) and nu/nu mice bearing FaDu tumors 
(n=13). Each tumor model contained a range of tumor volumes (MC38: 74.7 – 646.9 mm3 
measured using CT; FaDu: 51.2 - 302.1 mm
3
 measured using CT) to determine whether changes 
in vessel morphology and perfusion correlated with tumor growth. FaDu tumors larger than 400 
mm
3 
were not used because they had poor uptake of contrast agents, which made quantification 
of imaging parameters less reliable. Details regarding animals and tumor inoculation are 
provided in Supplementary Methods. 
 To determine whether vessel morphology and perfusion were altered with anti-
angiogenic treatment (cohort 2), C57BL/6 mice bearing MC38 tumors (n = 12 mice per group) 
were treated with anti-mouse VEGFR2 antibody (clone DC101, 500µg/dose, 27 mg/kg, 
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BioXCell) or Rat IgG1 (clone HRPN, 500 µg/dose, BioXCell). For in vivo microscopy 
experiments, C57BL/6 mice bearing MC38 tumors (n = 4 mice per group) were treated in the 
same way (24). Once tumors reached 30 mm
3
, intraperitoneal injections were administered every 
3 days for a total of 2 times (25). Tumors were imaged 6 days after start of treatment.  No 
toxicity or adverse events were observed during the treatment. Procedures were conducted in 
accordance with the UK Animal Scientific Procedures Act of 1986 (Project License Number 
30/2922) and were approved by the Committee on the Ethics of Animal Experiments at the 
University of Oxford. 
 
Preclinical imaging  
 In vivo imaging using CT and DCE-MRI was performed using the immobilization and 
imaging setup previously described to detect vessel structure and perfusion in the same tumor 
regions (22). In vivo imaging of vessel perfusion using multiphoton microscopy was performed 
to corroborate results of in vivo CT after anti-angiogenic treatment. Further details regarding 
instrument and scan settings are provided in Supplementary Methods. 
 
Patients 
 Baseline imaging data from 10 patients (mean age ± SD, 66 ± 9 y; 8 males and 2 females) 
with liver metastases (mean volume ± SD, 250 ± 270 cm
3
) from chemo-refractory colorectal 
cancer were used for the clinical cohort. Patients were enrolled in the PERFORM clinical trial 
(NCT01410760) and selected based on published criteria (26). Written consent was obtained 
from all patients.  Studies were conducted in accordance with Institutional Research Review 
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Board at the University of Oxford and the Berkshire Regional Ethics Committee (ref 
09/H0505/1). The clinical trial sponsor was the University of Oxford. 
 
Clinical imaging  
 Patients were injected intravenously with contrast agent (Omnipaque 300, 100 mL, 4 
mL/s) and were scanned using an abdominal CT scan 30 sec later (LightSpeed VCT, GE Medical 
Systems). CT images were acquired using X-ray tube settings of 120 kV, 307 µA, a 500 ms 
exposure per projection, and a voxel size of 0.85 x 0.85 x 0.63 mm
3
. MRI was performed on a 
1.5T or 3T scanner (Signa HDxt, GE Medical Systems) with respiratory triggering. Anatomical 
and T1-weighted images were acquired for tumor segmentation and pharmacokinetic modelling. 
DCE-MR images were subsequently acquired using a 3D gradient echo sequence (TE= 2.12 ms, 
TR = 4.46 ms, flip angle = 12°, voxel size = 0.9 x 0.9 x 2.5 mm
3
) after injection of contrast agent 
(ProHance Gadoteridol, 40 mL, 2 mL/s). Manual tumor segmentation was performed 
independently on CT and MRI scans. 
 
Quantification of in vivo imaging parameters  
 Vessel segmentation was performed on CT images (22) to quantify morphological 
parameters. Briefly, pre- and post-contrast scans were cropped to exclude non-tumor regions in 
the analysis, intensity normalized, co-registered using non-rigid registration, and then subtracted 
(Figure 1). Vessel structures were then segmented using a modified vesselness filter (27), and 
skeletonized using an iterative thinning algorithm (28) and an intensity-based gap filling model 
previously developed in our group (23). Because many cancer therapies are thought to normalize 
vascular structure in tumors, structural parameters such as vessel volume, branching points, 
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diameter, length, and tortuosity were chosen to characterize morphological changes (1). Total 
vessel volume was calculated by summing the voxels within segmentation, while the total 
number of branching points was calculated by summing the number of voxels in the skeleton 
with at least 3 adjacent skeleton voxels. Diameter was computed using a distance transform on 
the vessel segmentation and tortuosity was computed as previously reported (29). 
 MR images were segmented and processed as previously described (30) to quantify 
functional parameters. Images from patients were corrected for motion using non-rigid image 
registration based on the Diffeomorphic Demons modified by use of the Normalized Gradient 
Fields and the adaptive regularization scheme (31). Details of the current implementation are 
described elsewhere.  Because preclinical tumors were imaged with a surface coil to avoid 
motion, only voxels with K values > 0.6 were analyzed because of the limited depth of 
penetration of the surface coil. Beyond this distance, the signal-to-noise was unacceptable and 
the T1 mapping calculation began to break down (Supplementary Figures 1a-b). The initial area 
under the curve (iAUC90) was calculated by integrating the gadolinium (Gd) concentration curve 
up to the first 90 seconds after injection. K
trans
 was calculated from the Tofts model (32) using a 
population averaged arterial input function (33) for preclinical tumors and was calculated using 
PKView software (34)  for clinical tumors. We also quantified a third MR parameter, the fraction 
of voxels that enhanced at the first time point after injection (BATfrac). Although this parameter 
is not frequently used, it is calculated independent of pharmacokinetic models and is sensitive to 
changes induced by cancer therapy (30). The tumor was split into two regions, rim (1/3 of the 
tumor volume) and core (2/3 of the volume) for spatial analysis of signal. These values were 
chosen because previous reports highlighted radial heterogeneity in these tumor regions (30). 
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Measurement of vessel density ex vivo 
 In vivo measurements of vessel density were confirmed using ex vivo sections of tumors.  
Immunofluorescence staining was performed on tissue sections to quantify perfused vessel 
coverage per viable tissue area and pericyte coverage, and H/E staining was performed to 
confirm necrosis. Since perfused vessels were already labelled with CD31, only staining against 
the pericyte marker NG2 was performed. Sections containing the entire tumor were imaged using 
fluorescence microscopy (Nikon Ti-E, Nikon Instruments Europe B.V.), and staining was 
quantified using an automated algorithm, as previously described (35). Further details regarding 
staining and quantification are provided in Supplementary Methods. 
 
Statistical analysis 
 We fit linear models using ordinary least square regression (R Project, v. 3.4) to test the 
dependency of each MR parameter on CT parameters. For mouse tumors, linear models for 
iAUC90, K
trans
, and for BATfrac were generated using data from the cohort of mice from cohort 1. 
To simplify statistical analysis, the median value from log-transformed histograms of each 
imaging parameter was used for each mouse. We tested the dependence of each MR parameter 
on the following parameters: tumor region, tumor type, vessel volume, vessel radius, and vessel 
tortuosity. Because vessel volume, branching points, and vessel length were all strongly, linearly 
correlated (Pearson R
2
 = 0.97) with one another, and because vessel volume correlated with 
tumor volume (Pearson R
2
 = 0.91), we used only vessel volume in the model search to avoid 
violating the assumption that variables in linear models are independent.  
 An initial model search was performed to select the model that minimized the Bayesian 
information criterion. Model searches were performed using the stepAIC function in R (v. 3.4), 
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where the search was initialized from a model containing all main effects. The scope of the 
search contained all main effects and all possible interaction effects. StepAIC was allowed to add 
and subtract effects. Residuals were checked for homoscedasticity, normality, and outliers. After 
linear models were chosen for cohort 1, they were then applied to cohort 2. To test 
reproducibility of the linear models, we applied the models on the imaging data from the control 
IgG- treated mice and evaluated them for goodness of fit using a sum of squares F-test, with a 
threshold of P < 0.05. To determine whether DC101 treatment had altered the relationships 
between vessel structure and function, the models were then applied to the imaging data from the 
DC101-treated mice and tested for goodness of fit. Finally, we performed a model search for 
iAUC90 and K
trans
 to test whether the preclinical relationships held true for human tumors. 
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RESULTS  
In vivo quantification of vascular parameters indicates vascularity of preclinical tumor models 
The methodology for in vivo validation of MR parameters was optimized in two 
preclinical tumor models known to produce different levels of vascularization (36,37): mouse 
MC38 (high) and human FaDu (low). After tumors were imaged sequentially using CT and MRI, 
images were segmented into subregions (rim vs core) to quantify spatial relationships between 
structural parameters (vessel volume, branch density, length, radius, and tortuosity) from CT 
images and functional parameters (iAUC90, K
trans
, and BATfrac) from DCE-MR images (Figure 1; 
Supplementary Figures 1a-b). Repeated imaging of the same tumor during growth was not 
possible because the radiation dose from the CT scans was sufficient to curb tumor growth 
(Supplementary Figure 2). Thus, we imaged untreated tumors (henceforth cohort 1) consisting of 
a range of volumes from each tumor model to investigate the dynamics of vessel structure and 
function.  
Structural parameters derived from CT images reflected the degree of vascularity in the 
two tumor models. Although vessel volume was linearly correlated with tumor volume and with 
branch density in both tumor models (Figures 2a-b), the degree of vascularization was 
significantly higher in MC38 than in FaDu (Figure 2c).  Other vascular parameters (vessel 
length, radius, and tortuosity) were also significantly higher in MC38 than in FaDu (Figures 2d-
f) and were poorly correlated with tumor volume (Supplementary Figure 3). Nevertheless, we 
normalized for tumor volume in our subsequent analysis to avoid it being a confounding 
variable. Because the spatial resolution of the CT scan was 80 µm, we visualized perfused 
vessels (labeled with intravenously injected CD31) ex vivo to verify the degree of vascularization 
measured in vivo (where only perfused vessels were measured). MC38 tumor sections contained 
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perfused vessels that were evenly distributed across entire tissue sections, while FaDu tumors 
contained perfused vessels in the periphery and contained large, central regions of necrosis 
(Figure 2g). Vascular parameters (vessel/tumor volume, length, and radius) quantified from ex 
vivo sections corroborated the in vivo results (Figures 2h-j), with the exception of vessel 
tortuosity, which was higher in ex vivo sections of FaDu tumors (Figure 2k). 
DCE-MR parameters of vessel function also reflected the degree of vascularity in the two 
tumor models. The parameter iAUC90, which is used as a surrogate for tumor perfusion, was 2-
fold higher in MC38 tumors than in FaDu tumors (Figure 2l). Similar results were obtained for 
the parameter, K
trans
, which is a composite measure of blood flow and vessel permeability 
(Figure 2m). The parameter BATfrac, reflecting the fraction of voxels that enhanced at the first 
time point after bolus injection, was 5-fold higher in MC38 tumors than in FaDu tumors (Figure 
2n). Thus, these data confirm that the different levels of vascularization could be measured at 
both the structural and functional level in vivo. 
 
Functional MR parameters primarily reflect vessel density in preclinical tumors 
Next, to determine whether functional MR parameters were linked to structural CT 
parameters in untreated tumors (cohort 1, Figure 3a), vascular parameters extracted from the 
same tumor regions on CT and MR (Figures 1 and 3b) were analyzed using linear models 
(Supplementary Figure 4). The functional MR parameters, iAUC90 (Figure 3c) and K
trans 
(Figure 
3d) had a positive, linear relationship with vessel volume. However, vessel volume varied by 
both the tumor model (P = 0.001) and tumor subregion (P = 3e-10, Figures 3c-d).  No other 
structural parameter was found to significantly influence iAUC90 or K
trans
 values in untreated 
tumors (Supplementary Table 1, equations 1-2). The MR parameter BATfrac depended on vessel 
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volume and radius (Supplementary Table 1, equation 3), and varied by tumor subregion and 
tumor model (Figure 3e). Taken together, these results indicate that functional parameters are 
linked primarily to vessel density in untreated tumors, and that this link varies by vascularity and 
subregion. 
 
Anti-angiogenic treatment alters functional-structural relationship in preclinical tumors 
We then investigated whether anti-angiogenic therapy alters the relationship between 
functional and structural parameters. Mice bearing the highly vascularized MC38 tumor (cohort 
2) were imaged using CT and MR (Figure 4a) after a course of IgG antibody or the anti-VEGF 
receptor 2 antibody (DC101, 27 mg/kg). Treatment with DC101 significantly reduced tumor 
growth (Figure 4a), reduced mean vessel length in the rim (Figure 4b) and tortuosity in the core 
(Figure 4c), and increased iAUC90 values across the whole tumor (Ftreatment (1,42) = 4.88, P = 
0.026; two-way ANOVA; Figure 4d); it did not alter K
trans 
values (Figure 4e). However, vessel 
volume (normalized to tumor volume) was not different between the groups when measured by 
CT (P = 0.48, Figure 4b).  We used in vivo imaging of vessel perfusion using multiphoton 
microscopy to confirm that DC101 exerted an antiangiogenic effect (Figure 4f).  Ex vivo analysis 
of perfused vessels showed a 44% decrease in density, a 35% decrease in vessel number, and 
16% decrease in vessel length in DC101-treated tumors (Figures 4g-ji), consistent with vascular 
regression. To assess whether features of vascular normalization were present, we measured 
pericyte coverage using NG2 in ex vivo sections (Figure 4k). Treatment reduced pericyte 
coverage, the percent of pericytes associated with vessels, and increased vessel tortuosity 
(Figures 4l-n). These results confirm that DC101 exerted an antiangiogenic effect, although its 
effects were less prominent in vivo than ex vivo. 
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Anti-angiogenic therapy changed the relationship between functional and structural 
parameters (Figures 4c-e), as determined by the goodness of linear model fits (Supplementary 
Table 2; Supplementary Figures 5-6).  The dependency of iAUC90 on vessel volume was 
reproducibly measured in control tumors (P = 0.03), but was not measured in DC101-treated 
tumors (P = 0.204; Supplementary Table 2, equation 1).  A new model search for DC101-treated 
tumors was not significant at α = 0.05, but it provides weak evidence of a relationship between 
iAUC90 and vessel tortuosity (P = 0.051; Supplementary Table 2, equation 2).   The model fit 
for the dependency of K
trans
 on vessel volume was not statistically significant in either control 
tumors (P = 0.078) or in DC101-treated tumors (P = 0.145; Supplementary Table 2, equation 3). 
The linear model for BATfrac from cohort 1 showed a dependency of this parameter on both 
vessel volume and vessel radius. The dependencies partly reproduced in the control tumors of 
cohort 2 (vessel volume: P = 0.009; radius: P = 0.241), but not in the DC101-treated tumors of 
cohort 2 (vessel volume: P = 0.34; radius: P = 0.60; Supplementary Table 2, equation 4).  
 
Functional parameters reflect vessel morphology in human tumors 
Finally, to test whether this 3D biological validation strategy would be clinically feasible, 
we imaged 10 patients with chemorefractory liver metastases from colorectal cancer using 
arterial phase CT and DCE-MRI (Figure 5a). Despite the images being acquired on different 
imaging scanners, tumor volumes segmented from both CT and MRI were significantly 
correlated (Figure 5b).  Analysis of vascular and functional parameters within lesions (Figure 5c) 
revealed that MR parameters depended on structural parameters (Supplementary Table 3 and 
Supplementary Figure 7), although the calculated relationships were more complex than those 
measured in preclinical tumors.  We found that iAUC individually depended on vessel volume, 
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radius, and tortuosity, as well as on the interaction among all the parameters (Figure 5d; 
Supplementary Table 3, equation 1). That is, the parameters all modify each other’s effect on 
iAUC. For example, for constant values of vessel radius and tortuosity, an increase in vessel 
volume would decrease iAUC. K
trans
 depended on vessel volume, radius, and tortuosity (Figure 
5e; Supplementary Table 3, equation 2). Thus, functional parameters reflect a combination of 
structural parameters in liver metastases. 
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DISCUSSION  
Use of vascular parameters from in vivo CT for validation of functional MR parameters 
To improve imaging-biological validation of MR parameters, we developed a novel 
method that uses DCE-MRI and CT to measure the relationship between vessel function and 
structure in vivo and demonstrated feasibility of applying it to imaging of patients with cancer. 
Our method has detected key biological differences in vascular parameters of preclinical tumors 
across two tumor models and with anti-angiogenic treatment, and measured vascular parameters 
in patients with liver metastases from colorectal cancer. By linking functional MR parameters to 
specific aspects of vessel structure, our study provides information that can be used to inform the 
application of DCE-MRI in the clinic.   
Using contrast-enhanced CT in vivo, we measured structural parameters such as vessel 
volume, radius, length, and tortuosity for vessels ≥ 80 µm in preclinical tumors. Although this 
resolution does not allow for visualization of smaller vessels, we were nevertheless able to 
measure changes in vascular morphology. In vivo vascular parameters (vessel volume, length, 
and diameter) for the highly vascularized, untreated MC38 tumor model were significantly 
higher than in the poorly vascularized, untreated FaDu tumor model, consistent with ex vivo 
measurements of those parameters and with previous observations (36,37). Vessel volume and 
branching density also increased linearly with tumor volume in accordance with previous data 
(38–40). Finally, when MC38 tumors were treated with DC101, significant changes in vessel 
tortuosity and vessel length were measured, consistent with previous reports on the effect of this 
anti-angiogenic agent at this dose (24,38). Together, our results show that most vascular 
parameters derived from in vivo CT are consistent with those obtained from ex vivo CT scans or 
microscopic imaging performed at higher resolutions (1-50 µm range, (38,40)).  
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Although a few previous studies attempted to investigate the relationship between 
functional and structural parameters using multimodal imaging  (41–43), the work performed 
here overcomes three methodological limitations of those studies. Firstly, we used 3D volumetric 
techniques in both our imaging modalities (DCE-MRI and CT), whereas previous studies used 
2D regions of interest or 2D parameters for analysis of vessel structure, such as vessel surface 
area (41–43). As a result, volumetric analysis allowed us to analyze data from entire tumor 
regions, as well as, to perform spatial analysis based on tumor periphery and core-- in line with 
recent consensus recommendations for biomarker validation (21). Secondly, our analysis was 
performed using improved alignment methods of multimodal images that substantially reduce 
motion artifacts in both preclinical and clinical tumors (22,44). In contrast, previous studies did 
not correct for motion artifacts, which can cause misalignment in the images from the different 
modalities and severely reduce the resolution of rendered vessels (22).  Thirdly, the imaging was 
performed in vivo, avoiding the need to excise the tumor to image vessel architecture. It also 
demonstrates that structural and functional parameters, in principle, could be mapped in vivo in 
the same tumor over time to assess how and whether relationships change during the course of 
treatment. We have previously shown the value of including perfusion CT or DCE-MR in early-
phase drug development of vasoactive agents (45). Although serial imaging using our approach 
would not be clinically possible due to the CT radiation dose, future work could use MRI 
sequences to improve imaging of vessel morphology without exposure to ionizing radiation (46).  
 
Limitations of an in vivo approach to measuring structural-functional relationships 
Given the restricted spatial resolution, one limitation of the in vivo method is that it likely 
only measures structural-functional relationships in larger vessels, and as such, has important 
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implications in the use of in vivo imaging to determine these relationships. For example, the 
discordance in measurements of vessel volume and tortuosity obtained by CT vs microscopy in 
the DC101-treated tumors suggests that different vessel types (i.e., feeder vessels and arterioles 
in CT vs capillaries in microscopy) were affected by treatment. Indeed, tumors have multiple 
types of vessels that stem from different growth mechanisms (47,48), have different sizes, and 
respond differently to angiogenic factors such as VEGF (49). If changes induced by a treatment 
were to primarily affect the capillary level through sprouting or pruning, then the effect of 
treatment on structural-functional relationships would not be measured. However, for larger 
vessels (detectable within the scanner resolution) affected by treatment, the technique could offer 
insight into how antiangiogenics or other drugs alter vessel structure and tumor blood flow 
because the uptake of the contrast agents depend on blood supply to the tumor.  
   
Relationships between functional and structural parameters of vessels 
We found that the MR parameter iAUC primarily reflects the volume of perfused vessels 
in preclinical tumors. This was evidenced by results from cohorts 1 and 2, which both 
independently showed that iAUC had a positive, linear dependence on vessel volume that 
separated based on the tumor subregion. Anti-angiogenic treatment likely affects this relationship 
because the model from untreated tumors of cohort 1 fit the control tumors of cohort 2, but not 
the DC101-treated tumors of cohort 2. Furthermore, a new model search suggested a positive, 
linear dependence between iAUC and vessel tortuosity in DC101-treated tumors of cohort 2. 
This change may have occurred due to a reduced number of smaller vessels (evidenced by the 
decrease in perfused vessels and in vessel-associated pericytes measured ex vivo in DC101-
treated tumors), and/or due to vascular normalization of larger vessels (evidenced by an overall 
 21 
increase in iAUC90 across the whole tumor in DC101-treated tumors and decrease in tortuosity 
measured in vivo). Published data suggest that vascular regression may be predominant at the 
time point of imaging (24,25,50), but our data also raises the possibility that treatment could 
affect smaller and larger vessels differently. A previous study suggested that iAUC and fractional 
blood volume may have a negative relationship in tumors treated with an anti-angiogenic agent. 
However, as they were not able to measure the nature of the relationship in untreated tumors, we 
cannot assess whether anti-angiogenic treatment affected the link between function and structure 
to make a meaningful comparison (43). Furthermore, control tumors in that study were imaged 
three days later than the treated tumors, when the tumor volume was 2-fold different between the 
two groups.  We attempted to avoid these confounding factors by first establishing the 
relationship between iAUC90 and structural parameters in a range of tumor volumes from 
untreated tumors, before testing these relationships in an independent cohort of tumors without 
and with treatment.   
In liver metastases, iAUC reflected vascular parameters in a similar way (i.e., positive, 
linear dependence). However, we found a complex relationship in liver metastases between 
iAUC and CT parameters that has previously not been demonstrated. Prior studies from clinical 
work have shown conflicting relationships between iAUC and single vascular parameters such as 
microvessel density (4). Importantly, these analyses performed univariate comparisons, which 
cannot take into account interactions between variables. In contrast, the multivariate analysis 
presented here is sensitive to interactions between vascular parameters, and we find evidence of 
these interactions in human tumors. Although our preclinical data stem from tumors injected 
subcutaneously (for optimization of the imaging method and analysis algorithms), our preclinical 
and clinical findings suggest that iAUC may be linked to anatomical features of tumor vessels, 
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which could provide some clarity on its biological interpretation. 
Similar results were found for K
trans
, which primarily reflected the vessel volume within 
our study. In preclinical tumors, K
trans
 had a positive, linear dependence on vessel volume in 
cohort 1 and was not reproduced with strong evidence in cohort 2, suggesting that the statistical 
power may not have been sufficient. As a result, we are unable to interpret the findings of the 
model fitting in the DC101-treated tumors in cohort 2, which also did not fit the initial model. 
We also did not measure any changes in K
trans
 with DC101 treatment in our study, possibly 
reflecting the variability in K
trans
 measurements or in biological response within individual 
tumors. Previous studies have shown that anti-angiogenics decrease blood flow, decrease 
tortuosity, and normalize vessels (11,15–17,46,51) that may have varied impact on functional 
MR parameters in a dose-dependent manner.  At lower doses, antiangiogenic therapy can exert a 
vascular normalizing effect that is expected to transiently increase perfusion and blood flow by 
reducing vessel density, leakiness, and/or tortuosity. However, at higher doses, treatment can 
exert a vascular pruning effect that is expected to decrease blood flow and increase tortuosity, 
which are changes that would likely decrease iAUC and K
trans
 (2). These varied responses 
highlight the importance of assessing both the functional and structural effects of anti-angiogenic 
therapy.   
In patients with liver metastases, we also found that K
trans
 had a positive, linear 
dependence on a combination of three structural parameters including vessel volume, tortuosity, 
and radius. These results indicate that K
trans
, which is often used as a functional  surrogate for 
vessel permeability (21), may be affected by morphological changes. Because the absolute value 
of K
trans
 varies between cases due to the parameter’s reliance on pharmacokinetic model fitting, 
many studies report a change in K
trans
 when investigating therapeutic response. If K
trans
 reflected 
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morphological changes, then it would potentially eliminate the need to quantify change and 
instead could provide a value that can be linked to morphological features.  
The last MR parameter we investigated, BATfrac, had mixed linear dependencies to 
vascular parameters in preclinical cohort 1. The parameter dependencies were partly reproduced 
in cohort 2, but all dependencies were lost with DC101 treatment, consistent with observations 
for the other two MR parameters. While this parameter is not used clinically, we previously 
showed that it was sensitive to changes induced by radiotherapy (30). Furthermore, because it 
does not require pharmacokinetic modelling, it would be easier to use if these relationships are 
reproduced in clinical scenarios.  
 
Potential translational impact of study 
DCE-MRI parameters, iAUC and K
trans
, have been used as imaging biomarkers to predict 
tumor response to antiangiogenic therapies, but how these parameters reflect changes at the 
vascular level has been unclear.  We performed multimodal imaging to determine whether MR 
imaging biomarkers of vascular function could be linked to structural features of tumor vessels in 
vivo. Our preclinical and clinical data demonstrate that MR parameters have a relationship to 
structural features, that the relationship varies by tumor region and vascularity, and that it is 
affected by anti-angiogenic therapy. By coupling functional parameters to structural ones, this in 
vivo method could potentially provide insight into why antiangiogenic therapies have varied 
functional responses, and as such, could potentially improve the use of these imaging biomarkers 
in clinical decision making in assessing the effect of antiangiogenic therapies.  
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FIGURE LEGENDS 
 
Figure 1. Schematic illustrating acquisition and analysis pipeline from multimodal imaging of 
vessel structure and tumour perfusion. After immobilization in holder, tumors were imaged 
sequentially using CT and DCE-MRI. Pre- and post-contrast images from CT were intensity 
normalized and corrected for motion using non-rigid registration, while those from MRI were 
corrected for RF inhomogeneity and normalized to injected gadolinium concentration. Once 
vessels and tumor regions were extracted using segmentation algorithms, structural and 
functional parameters were quantified. 
 
Figure 2. Known differences in vessel structure and function can be measured using CT and 
DCE-MRI in two preclinical tumor models with different levels of vascularization. (a-f)  
Structural vessel parameters (normalized vessel volume, branching points, length, diameter, and 
tortuosity) extracted from CT images from highly vascularized MC38 tumors and poorly 
vascularized FaDu tumors. Linear regressions are plotted with 95% CI. (g) Images of perfused 
vessels and H/E stains from MC38 tissue sections show even vessel distribution and negligible 
areas of necrosis (denoted by 'N'), whereas those from FaDu tissue sections show uneven vessel 
distribution and regions of necrosis. (h-k) Structural vessel parameters (normalized vessel 
volume, length, diameter, and tortuosity) quantified from whole ex vivo sections of MC38 and 
FaDu tumors. (l-n) Functional parameters, iAUC90 (mean initial area-under-the-curve at 90 
seconds after injection), K
trans
, and BATfrac (values of enhanced fraction at first time point after 
bolus injection) extracted from DCE-MRI images from MC38 and FaDu tumors. Box-whisker 
plots show median and percentiles (25
th
 and 75
th
 percentile) as boxes, and minimum and 
maximum values as whiskers (n = 16 mice with MC38 tumors; n = 13 mice with FaDu tumors). 
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*** P < 0.001, ** P < 0.01, * P < 0.05 by unpaired t-test with Welch’s correction. 
 
Figure 3. Functional parameters of tumor perfusion reflect changes in vessel morphology in 
untreated preclinical tumors in vivo and have an altered relationship to vessel morphology after 
antiangiogenic treatment. (a) Representative images of segmented vessels from CT and 
corresponding images of perfusion (iAUC) from a range of tumor volumes. (b) Pearson 
correlation between analyzed tumor volume on CT and MRI images.  (c-e) Relationship of MR 
parameters, iAUC, K
trans
, and BATfrac to morphological parameters (vessel volume, tortuosity, 
radius), tumor region (core vs rim), and tumor type (MC38 ‘high’ vs FaDu ‘poor’ 
vascularization), as identified by linear model analysis. (f) Representative images of segmented 
vessels from CT and of MR images of iAUC (mM * min) and K
trans
 (mL * g
-1
 * min
-1
) from 
control and DC101-treated MC38 tumors. Green vessels are in the rim, while red vessels are in 
the core. (g) Normalized vessel volume, as measured by CT, does not change with DC101 
treatment. Box-whisker plots show median and percentiles (25
th
 and 75
th
 percentile) as boxes, 
and minimum and maximum values as whiskers. (h-j) Relationship of iAUC and BATfrac, but 
not K
trans
, with morphological parameters is altered by DC101 treatment in MC38 tumors, as 
identified by linear model analysis.  
 
Figure 4. Anti-angiogenic treatment significantly affects tumor growth, and some morphological 
and functional parameters in MC38 tumors. (a) Treatment with the anti-VEGFR2 antibody, 
DC101 (27 mg/kg), slowed growth of MC38 tumors. Growth curves represent mean ± SD from 
one experiment (n = 8 mice/group). Control tumors were treated with IgG (27 mg/kg). Arrows 
indicate days on which mice were injected with antibodies. (b-c) Treatment with the DC101 
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significantly decreased mean vessel length and tortuosity in the tumor rim and core, respectively. 
(d-e) DC101 treatment significantly increased iAUC90 across the whole tumor (Ftreatment (1,42) = 
4.88, P = 0.026; two-way ANOVA) even though its effect could not be isolated to a specific 
subregion. In contrast, K
trans
 values were not significantly different between controls and treated 
groups. (f) In vivo microscopy of perfused vessels visually confirms that DC101 destroys smaller 
vessels (10-50 µm, see inset) at the administered doses. (g) Representative images of staining for 
nuclei (blue) and vessels (green) in control IgG and DC101-treated tumors. Vessels shown are 
perfused; they were detected by i.v. injection of CD31-PE 10 min before tumor excision. Scale 
bar = 200 µm. (h-j) Perfused vessel coverage (per viable tissue area), the number of perfused 
vessels per tumor area, and vessel length decrease with DC101 treatment. (k) Representative 
images of staining for perfused vessels (green) and pericytes (magenta) in control IgG and 
DC101-treated tumors. Vessels shown are perfused; they were detected by i.v. injection of 
CD31-PE 10 min before tumor excision. Scale bar = 200 µm. (l-n) Pericyte coverage (per viable 
tissue area), the percent of vessel-associated pericytes (detected by NG2), and vessel tortuosity 
measured ex vivo in control and DC101 tumor sections. Box-whisker plots show median and 
percentiles (25
th
 and 75
th
 percentile) as boxes, and minimum and maximum values as whiskers. 
Data were pooled from two experiments (n = 12 mice total/group). * P < 0.05, ** P < 0.01, and 
*** P < 0.01 by one-way or two-way ANOVA followed by Bonferroni-corrected post t-tests or 
by Student’s t-test with Welch’s correction (unpaired, two-tailed, α =0.05). 
 
Figure 5. Functional parameters depend on structural parameters in human tumors. (a) 
Representative images from arterial phase CT and DCE-MRI scans from patients with liver 
metastases from colorectal cancer. (b) Pearson correlation between tumor volumes segmented on 
MR and CT images. (c) Representative images of vessel rendering and of K
trans
 maps from one 
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metastatic lesion. (d-e) Relationship of MR parameters, iAUC (mM * min) and K
trans
 (mL * g
-1
 * 
min
-1
), with morphological parameters, as identified by linear model analysis. 





